



The Problem: Heart disease is the leading killer in North America. Heart failure drives >1,000,000 U.S. hospital admissions annually—costing tens of billions of dollars—and most begin with the same preventable event: **fluid overload**.

The Solution: We are building a wearable monitoring platform that measures fluid directly so heart and liver patients stay healthy—and stay home.

Commercial Strategy: We sell first to specialist practices. Clinics gain recurring Remote Patient Monitoring (RPM) revenue under existing Medicare billing codes, robust patient engagement, and daily objective data. This pipeline builds clinical champions before we approach health systems—delivering 6- and 7-figure admission-avoidance economics.



Impelix Sensor Patch

DIRECT FLUID SENSING

** Concept mockup of future device; for demonstration purposes only.*

EXECUTION & DE-RISKING

- ✓ **Incorporated:** Federal incorporation complete (March 2026)
- ✓ **Quality System:** Controlled Quality Management System (QMS) in place
- ✓ **Published Science:** Peer-reviewed systematic review of wearable bioimpedance (2025)
- ✓ **Hardware:** Working functional research prototype
- ✓ **Safety Compliance:** IEC 60601-aligned electrical safety file
- ✓ **Clinical Protocol:** Finalized bilingual clinical trial protocol
- ✓ **Ethics & Approvals:** Hospital ethics review active; site clinical research director engaged; ITA process started

CAD \$15,000 bought all of this.

Companies routinely raise a full round to reach first-in-human trials. We are reaching this milestone on founder capital alone—under CAD \$35,000 all-in—and will not open our pre-seed round until that de-risked data exists. Every dollar raised buys aggressive commercial development, not basic proof of concept.

MARKET OPPORTUNITY

TAM

6.5M

North Americans with
fluid overload
conditions

SAM

3.5M

Outpatients requiring
specialist follow-up

SOM (1%)

\$18M

Annual Recurring Rev
capturing just 1% of
SAM

HIGHLY SCALABLE UNIT ECONOMICS

\$480

ANNUAL REV
Per Patient

\$130

TOTAL COGS
At Launch Scale

73%

GROSS MARGIN
\$350 Profit/Patient

Model: \$40/mo Device-as-a-
Service

Billing: Medicare CPT 99454 /
99457

MILESTONES & EXECUTION ROADMAP

- | | |
|----------------------|---|
| Late 2025 | Systematic review published |
| Mar 2026 | Incorporated; controlled QMS operational |
| Q3 2026 | Protocol finalized; hospital ethics review initiated |
| ○ Win 2026-27 | First-in-patient clinical feasibility study execution |
| ○ Q1 2027 | Provisional patent filing; trial data readout |
| ○ Spring 2027 | Pre-seed capital round officially opens |

TEAM & KEY ADVISORS

Adam Hofmann, MD — CEO, Internal Medicine

Guillaume Gibeau, MD — Cardiologist, Principal Investigator

Shania Tubana-Dean — Co-Founder, Product & Regulatory Lead

Emily Porter, PhD — Engineering Advisor (Consulting), Impedance

Thomas Coady — Engineering Lead, Quality & Electrical Safety

THE ASK

We are currently bootstrapping Impelix Health Inc. through to our first-in-patient data readout. Not raising today—our pre-seed round officially opens Spring 2027. Reply to join our quarterly one-page update list and track our execution firsthand. We report milestones met and missed—no claims ahead of data.

Adam Hofmann, MD

adam@impelix.health

Toronto, Ontario · Canada